Can BMY's Growth Portfolio Counter Legacy Drugs Decline in Q1?
Summary
BMY pivots to growth portfolio as legacy drugs decline, with rising new therapies helping offset revenue erosion and reshape the long-term outlook.
Description
BMY pivots to growth portfolio as legacy drugs decline, with rising new therapies helping offset revenue erosion and reshape the long-term outlook.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source